SERA PROGNOSTICS, INC. Proceeds from Sale of Debt Securities, Available-for-sale
SERA PROGNOSTICS, INC. (SERA) reported Proceeds from Sale of Debt Securities, Available-for-sale of $2.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- SERA PROGNOSTICS, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- SERA PROGNOSTICS, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- SERA PROGNOSTICS, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- SERA PROGNOSTICS, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $2.50M, a 50.00% decline from fiscal 2024.
- SERA PROGNOSTICS, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $5.00M.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $2.50M 10-K · filed 2026-03-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.50M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $2.50M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $5.00M 10-K · filed 2026-03-18 | ||
| 2024-09-30 | $5.00M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |